No Data
Express News | Humacyte Announces Planned Ind Filing in 2025 to Support First-in-Human Clinical Study of Small-Diameter Atev™ for Coronary Artery Bypass Grafting
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV for Coronary Artery Bypass Grafting
Express News | D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
Humacyte Provides Update on Commerical Launch, Pricing of Symvess
Humacyte Analyst Ratings
Express News | Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (Acellular Tissue Engineered Vessel-Tyod) for Extremity Vascular Trauma